(-)-epigallocatechin 3-gallate/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Inhibits SLCO1A2
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“EGCG competitively inhibited OATP1A2-mediated uptake of sulphobromophthalein and nadolol with Ki values of 21.6 and 19.4 μM, respectively.”
Quoted verbatim from Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers.. - Study
- in vitro · not in humans
- Population
- human embryonic kidney 293 cells stably expressing OATP1A2
Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers.2018PMID:29480324Permalink
Keep reading
- Everything the graph holds on (-)-epigallocatechin 3-gallate
- Every compound studied against SLCO1A2
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M2PD37ZPSS9WVT0T79N7VFJY